PRODUCT
Kaken Secures Japanese Rights for Alumis’ Novel TYK2 Inhibitor ESK-001
Alumis, Kaken Pharmaceutical, ESK-001, TYK2 inhibitor, dermatology, licensing agreement, Japan
Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3
Neo-1, Study models, molecular glues
ReSync Bio, Sapio Sciences adopt Nvidia BioNeMo to supercharge AI drug discovery
Drug Discovery, Aortic Valve Insufficiency, Sapio, Sapio Sciences, Bio, NVIDIA ‘s, BioNeMo, microservices
Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal
Servier, Black Diamond Therapeutics, BDTX-4933, solid tumors, licensing agreement, RAS/RAF inhibitor
Curevo Secures $110M for Advanced Shingles Vaccine Development
Curevo Vaccine, amezosvatein, shingles vaccine, Series B funding, improved tolerability, Shingrix competitor
Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout
Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms
Carvykti, Johnson and Johnson, Investments, J&J, Facility (object), Multiple Myeloma, production, competition
Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate
Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist
FDA Approves First Treatment for Macular Telangiectasia Type 2 (MacTel)
ENCELTO, revakinagene taroretcel-lwey, MacTel, FDA approval, encapsulated cell therapy, ciliary neurotrophic factor (CNTF)